Analysis of Measles and Rubella Immunoglobulin G Titers in COVID-19 Patients
Eşe Başbulut,Melek Bilgin,Hacer İşler,Ahmet Şen,Süleyman Kılıç,Mahcube Çubukçu
DOI: https://doi.org/10.2147/rmhp.s472872
2024-11-17
Risk Management and Healthcare Policy
Abstract:E&scedile Ba&scedilbulut, 1 Melek Bilgin, 1 Hacer I&scediller, 1 Ahmet &Scedilen, 2 Süleyman S&inodotrr&inodot K&inodotl&inodotç, 3 Mahcube Çubukçu 4 1 Department of Medical Microbiology, Samsun Training and Research Hospital, Samsun, Turkey; 2 Department of Anesthesia and Reanimation, Trabzon Faculty of Medicine, Trabzon, Turkey; 3 Department of Infectious Disease and Clinical Microbiology, Samsun Training and Research Hospital, Samsun, Turkey; 4 Department of Family Medicine, Samsun University Faculty of Medicine, Samsun, Turkey Correspondence: Mahcube Çubukçu, Tel +905052332232, Fax +903623111522, Email Background: The objective of this study is to compare the measles immunoglobulin G (IgG) and rubella IgG levels in patient groups with mild and severe COVID-19 disease and reveal the possible relationship. Methods: This study was conducted among COVID-19-confirmed patients over 18, under 65 years of age. This study involved 75 participants- divided into two groups. The first group usually comprised asymptomatic patients who did not require hospitalization (n=43), and the second group consisted of patients who had diffuse pneumonia on thoracic CT and required hospitalization (n=32). Results: Anti-measles and anti-rubella IgG titers were detected to be higher in the group with severe disease compared to the group with mild disease (p=0.001 and p=0.001, respectively). The analyses were repeated by taking n=27 in Group 1 and n=27 in Group 2, which were similar in terms of age, gender and number. In the analysis performed without any age difference between the groups, no significant difference was found between the two groups in terms of Anti Measles IgG antibody titers (p=0.068). However, Anti Rubella antibody titers were found to be higher in the group with severe COVID-19 disease than in those with mild disease (p=0.03). Regardless of the severity of the disease, there was a positive correlation between Anti Rubella and Anti Measles IgG antibody titers and age (p=< 0.001 Spearman's rho 0.517; p=0.008 Spearman's rho 0.304, respectively). Conclusion: We believe that the pre-existing Anti-Rubella IgG antibodies in the patient may increase in parallel with the patient's viral load by recognizing the common macrodomain of SARS-CoV-2 and Rubella viruses. The common macrodomain of SARS-CoV-2 and Rubella viruses is also present in the attenuated rubella virus used in the MMR vaccine4. In this case, we predict that previously administered MMR vaccine may be protective for COVID-19 patients. disease compared to those with mild disease. Keywords: COVID-19, measles, rubella, antibody, SARS-CoV-2, immunoglobulin G The clinical course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may be asymptomatic, or it may result in respiratory failure, pneumonia, and death. 1 The world continues to witness the rapid transformation of the SARS-CoV-2 virus with the Omicron variants (BA.1, BA.2, BA.3, BA.4, and BA.5) of the SARS-CoV-2 virus. The continuous change of Omicron variants brings about considerable challenges in establishing herd immunity for SARS-CoV-2. 2 However, vaccines help significantly reduce disease severity. 3 The fact that COVID-19 vaccines and effective antiviral drugs are still inaccessible in middle- and low-income countries and inequality in access to vaccines increase the risk of COVID-19 infection in low-income countries, mostly in Africa, and the likelihood of the emergence of new variants of the SARS-CoV-2 virus. 2,3 Studies have reported that COVID-19 infection is severe, especially in the elderly and adult population with a single comorbidity, while the disease progresses with mild symptoms in young people and the pediatric age group. 4–6 Likewise, it has been stated in the literature that children are less likely to be infected in other epidemics with viruses from the same family as the SARS-CoV-2 virus, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). 7 A reason for this difference may be associated with the more recent immunization of children with multiple vaccines such as Bacillus Calmette–Guérin (BCG), Diphtheria-Pertussis and Tetanus (DPT), hepatitis B, polio, and Measles-Mumps-Rubella (MMR). 8 Furthermore, some vaccines, such as BCG, may provide cross-protection against other pathogens not related to Mycobacterium tuberculosis. 9 The BCG vaccine has been shown to provide non-specific protection against pathogens such as Candida albicans, Staphylococcus aureus, and various respiratory viruses. 10–13 The said type of immu -Abstract Truncated-
health care sciences & services,health policy & services